Ajanta Pharma
BSE: 532331
|
NSE: AJANTPHARM
Ajanta Pharma
(CIN: L24230MH1979PLC022059)
operates in the Pharmaceuticals industry and has been listed in the stock market since 05 Jun 2000.
It currents trades on NSE with symbol AJANTPHARM and on BSE with scrip code 532331.
The registered office of the company is Ajanta Tower, 54-A, M.V. Road, Chakala, Andheri (East), Mumbai, Maharashtra - 400093.
The management team of Ajanta Pharma is led by Mannalal B. Agrawal who is the Non-Executive - Non Independent Director-Chairperson related to Promoter. Other members of the management team consist of Arvind K Agrawal (Designation:Chief Financial Officer), Madhusudan B. Agrawal (Designation:Executive Director), Yogesh Mannalal Agrawal (Designation:Executive Director-MD), Rajesh Mannalal Agrawal (Designation:Executive Director), David Rasquinha (Designation:Non-Executive - Independent Director), Medha Vinay Joshi (Designation:Non-Executive - Independent Director), Rajesh Shashikant Dalal (Designation:Non-Executive - Independent Director), Simi Manohar Lal Thapar (Designation:Non-Executive - Independent Director), Gaurang Shah (Designation:Company Secretary & Compliance Officer), .
The price and other financial information of Ajanta Pharma is as below -
The registered office of the company is Ajanta Tower, 54-A, M.V. Road, Chakala, Andheri (East), Mumbai, Maharashtra - 400093.
The management team of Ajanta Pharma is led by Mannalal B. Agrawal who is the Non-Executive - Non Independent Director-Chairperson related to Promoter. Other members of the management team consist of Arvind K Agrawal (Designation:Chief Financial Officer), Madhusudan B. Agrawal (Designation:Executive Director), Yogesh Mannalal Agrawal (Designation:Executive Director-MD), Rajesh Mannalal Agrawal (Designation:Executive Director), David Rasquinha (Designation:Non-Executive - Independent Director), Medha Vinay Joshi (Designation:Non-Executive - Independent Director), Rajesh Shashikant Dalal (Designation:Non-Executive - Independent Director), Simi Manohar Lal Thapar (Designation:Non-Executive - Independent Director), Gaurang Shah (Designation:Company Secretary & Compliance Officer), .
The price and other financial information of Ajanta Pharma is as below -
Volume: 1,749.00
M. Cap: 39,707.86
P/E: 37.60
Prev. Close: 3,253.70
Day
52 Wk
Volume: 37,311.00
M. Cap: 39,739.10
P/E: 37.60
Prev. Close: 3,255.70
Day
52 Wk
Stock Price Chart
F&O Data
Shareholding Pattern
| Category | No. of shares | Percent(%) |
|---|---|---|
| Promoters | 8,27,63,777 | 66.25 |
| Pledge | 1,48,45,582 | 17.94 |
| Foreign Institutions | 1,03,25,309 | 8.26 |
| Financial Institutions | 2,29,44,968 | 18.36 |
| NBFC and Mutual Funds | 1,90,16,704 | 15.22 |
| Others | 89,01,570 | 7.12 |
| Total | 15,87,97,910 | 133.15 |
Financial Data
Consolidated
| Figures in crore | 2026 | 2025 | 2024 |
|---|---|---|---|
| Net Sales | 5,452.86 | 4,648.10 | 4,208.71 |
| Operating Profit | 1,566.90 | 1,354.00 | 1,256.54 |
| Other Income | 172.07 | 94.50 | 84.60 |
| Interest | 16.11 | 20.73 | 7.21 |
| Depreciation | 173.14 | 144.11 | 135.40 |
| Profit Before Tax | 1,377.65 | 1,189.16 | 1,113.93 |
| Tax | 321.65 | 268.77 | 297.76 |
| Profit After Tax | 1,056.00 | 920.39 | 816.17 |
| Share Capital | 25.07 | 25.07 | 25.27 |
| Reserves | 4,502.02 | 3,765.22 | 3,542.09 |
| Net Worth | 4,527.09 | 3,790.29 | 3,567.36 |
| Loans | 314.81 | 130.74 | 78.53 |
| Gross Block | 3,046.33 | 2,801.06 | 2,389.41 |
| Investments | 588.35 | 463.95 | 348.63 |
| Cash | 104.77 | 176.24 | 130.77 |
| Debtors | 1,853.88 | 1,182.74 | 1,246.84 |
| Net Working Capital | 2,128.55 | 1,518.79 | 1,561.62 |
| Operating Profit Margin (%) | 28.74 | 29.13 | 29.86 |
| Net Profit Margin (%) | 19.37 | 19.80 | 19.39 |
| EPS | 84.24 | 73.43 | 64.60 |
| Dividend (%) | 1,400.00 | 1,400.00 | 2,550.00 |
| Dividend Payout | 349.82 | 349.75 | 642.17 |
Standalone
| Figures in crore | 2026 | 2025 | 2024 |
|---|---|---|---|
| Net Sales | 4,845.92 | 4,322.04 | 3,971.12 |
| Operating Profit | 1,402.39 | 1,324.59 | 1,235.91 |
| Other Income | 204.40 | 119.87 | 116.48 |
| Interest | 2.59 | 4.60 | 6.80 |
| Depreciation | 168.77 | 139.93 | 132.16 |
| Profit Before Tax | 1,231.03 | 1,180.06 | 1,096.95 |
| Tax | 284.21 | 263.17 | 289.71 |
| Profit After Tax | 946.82 | 916.89 | 807.24 |
| Share Capital | 25.07 | 25.07 | 25.27 |
| Reserves | 4,198.46 | 3,600.24 | 3,388.30 |
| Net Worth | 4,223.53 | 3,625.31 | 3,413.57 |
| Loans | 89.33 | 114.49 | 73.77 |
| Gross Block | 2,996.35 | 2,759.58 | 2,355.33 |
| Investments | 606.24 | 481.84 | 367.14 |
| Cash | 90.55 | 49.72 | 63.06 |
| Debtors | 1,365.77 | 1,225.81 | 1,207.67 |
| Net Working Capital | 1,603.80 | 1,339.73 | 1,398.86 |
| Operating Profit Margin (%) | 28.94 | 30.65 | 31.12 |
| Net Profit Margin (%) | 19.54 | 21.21 | 20.33 |
| Earning Per Share (Rs) | 75.53 | 73.15 | 63.89 |
| Dividend (%) | 1,400.00 | 1,400.00 | 2,550.00 |
| Dividend Payout | 349.82 | 349.75 | 642.17 |
| Bonus History | Date | Ratio |
|---|---|
| 22 Jun 2022 | issue issue 1:2 |
| 17 Sep 2013 | issue issue 1:2 |
Financial Data Graph
The peers of Ajanta Pharma are LUPIN, GLAND and GLAXO. You can get more detailed information on those company by clicking on the respective names.
* The above data is collected from public sources and we do not guarantee the accuracy of the same.*
Popular Comments
No comment posted for this article.